Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535148 | 0.82 | PNMT (0.56) | TAAR1IDO1PNMTCYP1A2CYP3A4 | |
| SCHEMBL11480751 | 0.82 | GABRA1 (0.36) | TAAR1IDO1CYP1A2LMNA | |
| SCHEMBL16958334 | 0.79 | ALDH1A1 (0.42) | TAAR1PNMTSMN1; SMN2LMNA | |
| SCHEMBL3245739 | 0.79 | TAAR1 (0.50) | TAAR1IDO1PNMTNPC1RAB9A | |
| SCHEMBL5325998 | 0.78 | IDO1 (0.52) | TAAR1IDO1PNMTCYP1A2CYP3A4 | |
| SCHEMBL5537535 | 0.77 | TAAR1 (0.54) | TAAR1IDO1PNMTNPC1RAB9A | |
| SCHEMBL2953963 | 0.76 | PKM (0.52) | TAAR1IDO1PNMTCYP1A2CYP3A4 | |
| SCHEMBL1020369 | 0.76 | IDO1 (0.50) | TAAR1IDO1PNMTCYP1A2CYP3A4 | |
| SCHEMBL3714690 | 0.76 | PTGS2 (0.60) | CYP3A4CYP2C9LMNATSHR | |
| Hydrochloric Acid SCHEMBL7824228 | 0.74 | IDO1 (0.48) | TAAR1IDO1PNMTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | claimed |
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| WO-2015109451-A1 | SYNTHESIS OF COMPOUNDS CONTAINING 8-OXA-3-AZABICYCLO (3.2.1)OCTANE RING | RHODIA OPERATIONS (FR) | 2015-07-30 | — | — | WO | claimed |
| EP-2042491-A1 | Pyridazines as fungicides | Bayer CropScience AG (DE) | 2009-04-01 | — | — | EP | claimed |
| US-7417027-B2 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | claimed |
| EP-1441750-A4 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2006-10-18 | — | — | EP | claimed |
| US-20020048774-A1 | Liquid phase parallel synthesis of chemical libraries | BRISTOL-MYERS SQUIBB PHARMA RESEARCH LABS, INC. | 2002-04-25 | — | — | US | claimed |
| US-6245937-B1 | COMBINATORIAL LIBRARIES OF CHEMICAL COMPOUNDS SYNTHESIZED BY BIPHASIC SYNTHESIS UTILIZING SPECIFIED TEMPLATES | DUPONT PHARMACEUTICALS RESEARCH LABORATORIES, INC. | 2001-06-12 | — | — | US | claimed |
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-5270342-A | Acetamide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | claimed |
| EP-0469887-A1 | Acetamide derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-4742061-A | Benzoc[c]-1,5-naphthyridines and related compounds as memory enhancing agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-03 | — | — | US | claimed |
| US-3975532-A | ANALGESIC | ICI UNITED STATES INC. (US) | 1976-08-17 | — | — | US | claimed |
| US-3953596-A | 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals | ICI UNITED STATES INC. (US) | 1976-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020048774-A1 | Liquid phase parallel synthesis of chemical libraries | CDK2, CDC25C, POLR2H | TAAR1 3279/4885IDO1 1450/4885PNMT 989/4885 |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | VIP, PEPD, NRDC | TAAR1 4703/4885IDO1 3245/4885PNMT 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.